Hisamitsu Pharmaceutical Co., Inc. (TYO: 4530)

Market Cap	331.34B
Revenue (ttm)	150.13B
Net Income (ttm)	15.54B
Shares Out	72.93M
EPS (ttm)	208.81
PE Ratio	21.76
Forward PE	20.42
Dividend	86.00 (1.87%)
Ex-Dividend Date	Feb 27, 2025

Volume	139,200
Average Volume	238,910
Open	4,570.00
Previous Close	4,595.00
Day's Range	4,530.00 - 4,600.00
52-Week Range	3,600.00 - 4,735.00
Beta	0.34
RSI	65.46
Earnings Date	Jan 9, 2025

About Hisamitsu Pharmaceutical Co.

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United St...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1847
• Employees: 2,759
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4530

Financial Performance

In 2023, Hisamitsu Pharmaceutical Co.'s revenue was 141.71 billion, an increase of 10.42% compared to the previous year's 128.33 billion. Earnings were 13.97 billion, an increase of 18.97%.